| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | HIV1-p24 |
| Uniprot No | P12497 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 133-363aa |
| 氨基酸序列 | PIVQNLQG QMVHQAISPR TLNAWVKVVE EKAFSPEVIP MFSALSEGAT PQDLNTMLNT VGGHQAAMQM LKETINEEAA EWDRLHPVHA GPIAPGQMRE PRGSDIAGTT STLQEQIGWM THNPPIPVGE IYKRWIILGL NKIVRMYSPT SILDIRQGPK EPFRDYVDRF YKTLRAEQAS QEVKNWMTET LLVQNANPDC KTILKALGPG ATLEEMMTAC QGVGGPGHKA RVL |
| 预测分子量 | 24 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于HIV-1 p24重组蛋白的文献摘要概括(注：文献为虚构示例，实际文献需通过学术数据库检索)：
1. **《Recombinant HIV-1 p24 protein as a sensitive antigen for early serodiagnosis》**
- 作者：Schupbach J, et al.
- 摘要：研究利用重组p24蛋白开发高灵敏度ELISA检测方法，证明其相比传统病毒裂解液抗原能更早检测到HIV-1感染，尤其在抗体窗口期显著提升诊断准确性。
2. **《Structural and functional characterization of HIV-1 p24 recombinant protein》**
- 作者：McKeating JA, et al.
- 摘要：通过X射线晶体学解析重组p24蛋白结构，揭示其与宿主细胞因子的相互作用位点，并验证其在病毒衣壳组装中的关键功能，为抗病毒药物设计提供依据。
3. **《Enhanced immune responses to HIV-1 p24 by fusion with heat shock protein》**
- 作者：Wang Y, et al.
- 摘要：将重组p24与热休克蛋白(HSP70)融合表达，显著增强小鼠模型中的Th1型免疫反应和特异性抗体滴度，提示其在HIV治疗性疫苗中的潜在应用。
如需真实文献，建议在PubMed或Web of Science中检索关键词：**"HIV-1 p24 recombinant" AND (detection/vaccine/structure)**。
HIV-1 p24 recombinant protein is a key structural component of the human immunodeficiency virus type 1 (HIV-1), playing a critical role in viral replication and pathogenesis. The p24 protein, encoded by the *gag* gene, forms the capsid shell that encloses the viral RNA and enzymes required for replication. It is highly conserved across HIV-1 strains, making it a valuable target for diagnostic assays, vaccine development, and therapeutic research.
During early HIV-1 infection, p24 is produced in large quantities as part of the Gag polyprotein, which undergoes protease-mediated cleavage to release mature viral particles. Detection of p24 in blood or tissues serves as a marker of acute infection, particularly during the "window period" before antibody responses develop. Recombinant p24 is produced using expression systems like *E. coli* or yeast, enabling scalable and cost-effective generation of purified protein for research and clinical applications. These systems often incorporate affinity tags (e.g., His-tag) to facilitate purification.
In diagnostics, recombinant p24 is widely used in ELISA and antigen tests to enhance early detection sensitivity. It also supports research on viral assembly, host immune responses, and drug targeting. Studies explore its potential as a vaccine antigen, though immune evasion mechanisms pose challenges. Additionally, p24 levels in plasma correlate with disease progression, aiding therapeutic monitoring. Its recombinant form eliminates biosafety risks associated with handling live virus, streamlining laboratory workflows. Current investigations focus on optimizing its immunogenicity and structural stability for next-generation interventions against HIV/AIDS.
×
